Edition:
United States

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

10.27EUR
9 Dec 2016
Change (% chg)

€0.52 (+5.33%)
Prev Close
€9.75
Open
€10.00
Day's High
€10.27
Day's Low
€9.94
Volume
101,985
Avg. Vol
214,985
52-wk High
€16.20
52-wk Low
€8.21

ABLX.BR

Chart for ABLX.BR

About

Ablynx NV is a Belgium-based biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx NV has more than 30 proprietary and... (more)

Overall

Beta: 1.47
Market Cap(Mil.): €625.67
Shares Outstanding(Mil.): 60.92
Dividend: --
Yield (%): --

Financials

  ABLX.BR Industry Sector
P/E (TTM): -- 41.98 30.40
EPS (TTM): -0.32 -- --
ROI: -8.19 -0.36 15.24
ROE: -17.46 -0.94 16.58

BRIEF-Ablynx 9-month net profit turns to 10.9 million euros

* 9-month revenue 68.9 million euros ($73.22 million) versus 53.6 million euros year ago

Nov 23 2016

BRIEF-FMR LLC announces 9.10 pct shareholding in Ablynx

* FMR LLC announces 9.10 pct shareholding in Ablynx Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 18 2016

BRIEF-Ablynx announces warrant exercise

* Additional 938 common shares have been issued by the company in exchange for 5,102.72 euros as the result of the exercise of warrants Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 10 2016

BRIEF-Ablynx announces warrant exercise

* Additional 10,050 common shares have been issued by the Company in exchange for 47,303 euros ($51,569.73) as the result of the exercise of warrants Source text for Eikon: Further company coverage: ($1 = 0.9173 euros) (Gdynia Newsroom)

Oct 21 2016

BRIEF-Ablynx outlines next steps for its anti-il-6r nanobody, vobarilizumab

* Ablynx outlines next steps for its anti-il-6r nanobody, vobarilizumab, a potential best-in-class treatment for rheumatoid arthritis

Oct 20 2016

BRIEF-Ablynx extends research collaboration with Merck & Co

* Ablynx announces second extension of its Ion channel research collaboration with Merck & Co

Oct 12 2016

BRIEF-FMR LLC announce 9.22 pct shareholding in ablynx

* FMR LLC announce 9.22 pct shareholding in Ablynx Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Oct 11 2016

BRIEF-Ablynx Initiates a phase III follow-up study of its first-in-class wholly-owned anti-vWF nanobody, caplacizumab, for treatment of acquired TTP

* Initiates a phase III follow-up study of its first-in-class wholly-owned anti-vWF nanobody, caplacizumab, for treatment of acquired TTP

Oct 10 2016

BRIEF-Ablynx to present additional data on caplacizumab

* Announces that it will today present additional data from post-hoc analyses of the Phase II TITAN study of its wholly-owned Nanobody, caplacizumab, in patients with acquired thrombotic thrombocytopenic purpura (aTTP)

Sep 29 2016

BRIEF-Ablynx H1 net income turns to profit of 22.8 million euros

* H1 total revenues were 53.5 million euros ($60.3 million), a 39 pct increase compared with 2015

Aug 25 2016

Earnings vs. Estimates